X4 Pharmaceuticals, Inc — Director's Dealing 2018

Mar 9, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Arsanis, Inc. (ASNS)
CIK: 0001501697
Period of Report: 2018-03-07

Reporting Person: STEVENS ANTHONY CHRIS (Chief Medical Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-03-07	Stock option (right to buy)	$17.34	A	50000	Acquired	2028-03-06	Common Stock (50000)	Direct

Footnotes

F1: This option becomes exercisable as to 25% of the shares underlying the award on the first anniversary of the date of grant, with the remainder vesting in equal monthly installments until the fourth anniversary of the date of grant.